Through its proprietary portfolio of new chemical entities (NCEs), SciFluor offers strategic partners the opportunity to greatly expand their pipeline of innovative medicines in a wide range of disease and therapeutic categories such as ophthalmic disease, central nervous system disorders, and inflammation.
SciFluor has two lead compounds in development:
SF0166 is a small molecule integrin antagonist designed to treat retinal disease, including Age-related Macular Degeneration (AMD) and Diabetic Macular Edema (DME), via topical administration to the eye. It is a potent and selective small molecule inhibitor of integrin αvβ3 with an optimum balance of physiochemical properties to allow it to distribute to the retina in high concentrations after topical administration. It has been tested in an extensive set of pre-clinical assays and shown to be effective in a validated in vivo model of wet-AMD. The non-fluorinated compound on which it is based does not distribute appreciably to the back of the eye after topical administration.
Age-related Macular Degeneration (AMD) is the most common cause of severe vision loss in older Americans. It affects central vision and may interfere with daily tasks such as reading and driving. Macular degeneration affects the retina in two forms – dry and wet AMD, also called neovascular AMD. Wet AMD is frequently accompanied by relatively sudden loss of vision. This is caused by the growth of abnormal blood vessels underneath the retina that leak fluid or blood. Recent advances in the treatment of wet AMD can now prevent further loss of vision, or even restore vision in some cases, if treatment is sought promptly. These treatments require frequent injections of biologic drugs into the back of the eye performed in a doctor’s office. Generally, the effectiveness of these treatments decreases with time, therefore improved treatments are actively being sought. A topically administered drug that is safe and effective would be a major advance in patient care.
SF0034 is a potent and selective KCNQ2/3 activator designed for suppressing neuronal hyperexcitability that may be a superior anti-epileptic drug (AED) for treating patients with partial-onset epilepsy. The mechanism of action of this drug may also show benefit in patients with other disease related to neuronal hyperexcitability, including a very rare form of pediatric encephalopathy, neurodegeneration, such as occurs in amyotrophic lateral sclerosis (ALS), and the acoustic nerve hyperexcitability-related condition, tinnitus.
Epilepsy is a relatively common condition, affecting 0.5% to 1% of the population. In the United States, about 2.5 million people have epilepsy and about 9% of Americans will have at least one seizure in their lifetimes. Epilepsy occurs as a result of abnormal electrical activity originating in the brain. Brain cells communicate by sending electrical signals in an orderly pattern. In epilepsy, these electrical signals become abnormal, giving rise to an "electrical storm" that produces seizures. These storms may be within a specific part of the brain or be generalized, depending on the type of epilepsy.
In addition to these development candidates, SciFluor has earlier-stage projects in ophthalmology, neurology, and additional therapeutic areas including fibrosis and inflammation.